Introduction: The Paradigm of Atrial Fibrillation-Mediated Cardiomyopathy
Atrial fibrillation-mediated cardiomyopathy (AFCM) represents a critical and often reversible subset of heart failure (HF) with reduced ejection fraction (HFrEF). In these patients, the arrhythmia itself—either through rapid ventricular rates, loss of atrial kick, or irregular rhythm—is the primary driver of ventricular dysfunction. Historically, once the rhythm is controlled and the left ventricular ejection fraction (LVEF) normalizes, clinicians have been faced with a therapeutic dilemma: should HF pharmacotherapy be continued indefinitely, or can it be safely withdrawn?
Current guidelines largely extrapolate from studies like TRED-HF, which examined dilated cardiomyopathy (DCM) and found high rates of relapse after medication withdrawal. However, AFCM is pathophysiologically distinct, as the inciting trigger (atrial fibrillation) can often be definitively addressed via catheter ablation. The WITHDRAW-AF trial was designed to provide evidence-based clarity on whether de-prescribing is a viable path for these patients.
